

REMARKS

Applicants hereby elect to prosecute Group III, Claims 1, 4 and 9 drawn to a methods of administration of an antagonist of EDG-1 signal transduction, further comprising an AKT kinase inhibitor, with traverse.

If there are any additional charges with respect to this Response or otherwise, please charge them to Deposit Account No. 06-1130 maintained by Cantor Colburn LLP.

Respectfully submitted,

TIMOTHY HLA ET AL

CANTOR COLBURN LLP
Applicants' Attorneys

By: Karen A. LeCuyer
Karen A. LeCuyer

Date: June 8, 2001
Customer No.: 23413
Telephone: (860) 286-2929